Colorectal Cancer Perspective

 
 
  • HER2+ Colorectal Cancer: Slicing the Pie Into Curable Portions   Dr John Marshall views a study of dual targeting in HER2+ CRC as an argument for combining broad molecular testing and precision medicine to slice the cancer pie into curable portions.
  • Colon Cancer Screening Made Easier   What do you do when a patient refuses a colonoscopy? Dr David Johnson offers commentary on a new blood-based screening test for colon cancer.
  • ASCO Policy Statement Supporting HPV Vaccination   Dr Maurie Markman explains his support for ASCO's recently published article supporting HPV vaccinations.
  • Metformin Active in Reducing Colorectal Polyp Recurrence   Dr David Kerr reports on a randomized study in which low-dose metformin reduced recurrence of colorectal polyps from 56% to 38%. Is metformin potentially another strategy to prevent colorectal cancer?
  • Genetic Test May Identify CRC Risk in 'Normals'   A study describes a genetic 'signature' able to identify normal individuals at higher and lower risk of developing colorectal cancer--which has strong implications for screening, says Dr David Kerr.
  • Survival Benefit of SIRT in mCRC Uncertain   Dr David Kerr looks at a study of selective internal radiation therapy in hepatic metastatic colorectal cancer, but says the lack of survival data puts the clinical utility of SIRT in question.
  • New Biomarker for Yea or Nay to Chemo in Early CRC   Dr David Kerr gives the thumbs-up to new data on CDX2, a prognostic biomarker whose absence identifies colorectal cancer patients likely to benefit from adjuvant chemo, but says validation is needed.
  • Too Much Surveillance in Early CRC: Not a Good Thing   Intensive surveillance after resection of early-stage colorectal cancer does not improve survival and adds cost without adding value, says Dr David Kerr, reporting on the findings of a recent study.
  • 'Releasing the Dogs’ in the Body’s War on Cancer   Drs Lou Weiner and Chris Heery vividly describe strategies that prompt the immune system to attack and kill cancer cells, and offer a view from the trenches of cancer immunotherapy.
  • Say No to Intensified Chemo in the Elderly   A study in patients with advanced colorectal cancer (median age, 80) found that adding irinotecan to 5-FU/leucovorin provided no benefit, prompting Dr David Kerr to assess chemo in the truly elderly.
  • CRC Builds Up STEAM in Midst of Blizzard   After digging out from a blizzard, Dr John Marshall discusses highlights from GICS 2016, including molecular testing, new drugs, and key studies results, plus the STEAM trial in colorectal cancer.
  • Delivering 'Bad' vs 'Serious' News to Patients There are guidelines for delivering bad news to patients that make the task less difficult for both doctors and patients and even help doctors promote better outcomes.
  • Metronomic Capecitabine as mCRC Maintenance Therapy   Dr David Kerr discusses a small study that provides provocative results for using metronomic, low-dose, oral capecitabine as single-agent maintenance therapy in advanced colorectal cancer.
  • Gastrointestinal Cancers Symposium (GICS) 2016 Read clinically focused news coverage of key developments from GICS 2016.
  • Why Is Colorectal Cancer Targeting the Young? The incidence of CRC in persons under 50 is increasing at an incredible pace, prompting experts at the 2015 Ruesch Center Symposium to grapple with how to understand and arrest this disturbing trend.
  • Is Capecitabine New Standard in Pre-op Rectal Cancer?   Dr David Kerr reports on a study in which oral capecitabine beat continuous-infusion 5-FU 'fairly and squarely' in tumor control of early rectal cancer, which may prove a new standard of practice.
  • In Cancer Screening, Why Not Tell the Truth? In cancer screening, have we let what we believe become what we know?
  • Can Coffee KO Cancer's Return?   Early data suggest that coffee intake may reduce the recurrence rate of colon cancer, prompting Dr David Kerr to question whether to recommend that CRC patients have another cup (or two) of joe.
  • Top 10 Practice Changers in Gastroenterology: 2015 Dr David Johnson looks back on a notable 12 months in published gastroenterologic research, and picks the data most likely to affect our practices for years to come.
  • Oral Adjuvant CRC Therapy: How Little Is Enough?   Dr David Kerr comments on a study reporting that 6 months of oral UFT/LV for stage IIB/III colon cancer therapy is as effective as 18 months of treatment. He asks: Can we shorten treatment further?
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.